Pre-OpenStock Movers:
Acutus Medical, Inc. (Nasdaq: AFIB) 49% HIGHER; announced a commitment letter from Deerfield Management Company (Deerfield), to refinance its existing debt with a new longer-term credit facility, and in conjunction with the refinancing, a definitive agreement to sell the Companys left-heart access portfolio to Medtronic (NYSE:MDT).
NCR Corp. (NYSE:NCR) 23% LOWER; reported Q1 EPS of $0.33, $0.30 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $1.86 billion versus the consensus estimate of $1.93 billion. NCR Corp. sees FY2022 EPS of $2.70-$3.20, versus the consensus of $3.39. NCR Corp. sees FY2022 revenue of $8 billion, versus the consensus of $8.11 billion.
Mattel (NASDAQ:MAT) 13% HIGHER; is talking to buyout firms to explore a potential sale, WSJ reported.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) 11% HIGHER; agreed to sell 953,834 of its common shares at a price of $26.21 per share to Pfizer (NYSE:PFE) for gross proceeds of $25.0 million
F5 Networks (NASDAQ:FFIV) 8% LOWER; reported Q2 EPS of $2.13, $0.12 better than the analyst estimate of $2.01. Revenue for the quarter came in at $634 million versus the consensus estimate of $634.08 million. F5 Networks sees Q3 2022 revenue of $660-680 million, versus the consensus of $693.15 million.
Enphase Energy (NASDAQ:ENPH) 8% HIGHER; reported Q1 EPS of $0.79, $0.13 better than the analyst estimate of $0.66. Revenue for the quarter came in at $441.3 million versus the consensus estimate of $432.28 million. Enphase Energy sees Q2 2022 revenue of $490-520 million, versus the consensus of $474 million
Microsoft (NASDAQ:MSFT) 7% HIGHER; posted Q3 EPS of $2.22, $0.04 better than the analyst estimate of $2.18. Revenue for the quarter came in at $49.4 billion versus the consensus estimate of $49.03 billion. Issues strong guidance.
Visa (NYSE:V) 7% HIGHER; reported Q2 EPS of $1.79, $0.14 better than the analyst estimate of $1.65. Revenue for the quarter came in at $7.2 billion versus the consensus estimate of $6.83 billion.
Lucid Group, Inc. (LCID) 5% HIGHER; the Government of Saudi Arabia agreed to purchase 100,000 vehicles over a ten-year period.
Chipotle Mexican Grill (NYSE:CMG) 4% HIGHER; reported Q1 EPS of $5.70, $0.06 better than the analyst estimate of $5.64. Revenue for the quarter came in at $2 billion versus the consensus estimate of $2.01 billion. Comparable restaurant sales increased 9.0%. Second quarter comparable restaurant sales growth, assuming current sales trends continue, in the 10% to 12% range.
Alphabet (NASDAQ:GOOGL) 4% LOWER; reported Q1 EPS of $24.62, $1.34 worse than the analyst estimate of $25.96. Revenue for the quarter came in at $68 billion versus the consensus estimate of $68.1 billion. Announced an additional $70.0 billion buyback.
Boeing (NYSE:BA) 4% LOWER; reported Q1 EPS of ($2.75), $2.63 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $13.99 billion versus the consensus estimate of $15.83 billion.
Texas Instruments (NASDAQ:TXN) 4% LOWER; reported Q1 EPS of $2.35, $0.17 better than the analyst estimate of $2.18. Revenue for the quarter came in at $4.91 billion versus the consensus estimate of $4.74 billion. Texas Instruments sees Q2 2022 EPS of $1.86-$2.26, versus the consensus of $2.27. Texas Instruments sees Q2 2022 revenue of $4.2-4.8 billion, versus the consensus of $4.94 billion.
Robinhood (NASDAQ:HOOD) 3% LOWER; letting go approximately 9% of our full-time employees.
Boston Scientific (NYSE:BSX) 3% HIGHER; reported Q1 EPS of $0.39, in-line with the analyst estimate of $0.39. Revenue for the quarter came in at $3.03 billion versus the consensus estimate of $2.95 billion. Boston Scientific sees Q2 2022 EPS of $0.41-$0.43. Boston Scientific sees Q2 2022 revenue of $0.44 billion. The company estimates net sales growth for the second quarter of 2022, versus the prior year period, to be in a range of approximately 3 to 6 percent on a reported basis and organic basis. Boston Scientific sees FY2022 EPS of $1.74-$1.79. Boston Scientific sees FY2022 revenue of $1.77 billion. The company now estimates net sales growth for the full year 2022, versus the prior year period, to be in a range of approximately 7 to 9 percent on a reported basis, and approximately 6.5 to 8.5 percent on an organic basis.